LitAlert ~~

    • An updated counseling framework for moderate-penetrance colorectal cancer susceptibility genes.
    • Breen KE, Katona BW, Catchings A, Ranganathan M, Marcell V, Latham A, Yurgelun MB, Stadler ZK.
    • Genet Med. 2022 Oct 12:S1098-3600(22)00918-2. doi: 10.1016/j.gim.2022.08.027. Epub ahead of print.
    • Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status.
    • Scott R, González-Martín A.
    • OncLive. 2022 Oct 12.

    Conference abstract:

    530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety.

    Identifier: NCT02655016: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. ( . Accessed 2022 Oct 12.)

    Video: Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer. (OncLive TV)